A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.
Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. ...
“As administrations change, federal agencies’ leadership often changes to align with the incoming president’s priorities,” ...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
Volta Medical put forward new data showing its artificial-intelligence-guided ablation procedures were able to improve ...
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results